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Abstract
Aims/hypothesis Impaired glucose uptake in skeletal muscle
is an important contributor to glucose intolerance in type 2
diabetes. The aspartate protease, beta-site APP-cleaving en-
zyme 1 (BACE1), a critical regulator of amyloid precursor
protein (APP) processing, modulates in vivo glucose disposal
and insulin sensitivity in mice. Insulin-independent pathways
to stimulate glucose uptake and GLUT4 translocation may
offer alternative therapeutic avenues for the treatment of dia-
betes. We therefore addressed whether BACE1 activity, via
APP processing, in skeletal muscle modifies glucose uptake
and oxidation independently of insulin.
Methods Skeletal muscle cell lines were used to investigate
the effects of BACE1 and α-secretase inhibition and BACE1
and APP overexpression on glucose uptake, GLUT4 cell
surface translocation, glucose oxidation and cellular
respiration.
Results In the absence of insulin, reduction of BACE1 activ-
ity increased glucose uptake and oxidation, GLUT4myc cell
surface translocation, and basal rate of oxygen consumption.
In contrast, overexpressing BACE1 in C2C12 myotubes
decreased glucose uptake, glucose oxidation and oxygen con-
sumption rate. APP overexpression increased and α-secretase
inhibition decreased glucose uptake in C2C12 myotubes. The
increase in glucose uptake elicited by BACE1 inhibition is
dependent on phosphoinositide 3-kinase (PI3K) and mim-
icked by soluble APPα (sAPPα).
Conclusions/interpretation Inhibition of muscle BACE1 ac-
tivity increases insulin-independent, PI3K-dependent glucose
uptake and cell surface translocation of GLUT4. As APP
overexpression raises basal glucose uptake, and direct appli-
cation of sAPPα increases PI3K–protein kinase B signalling
and glucose uptake in myotubes, we suggest that α-secretase-
dependent shedding of sAPPα regulates insulin-independent
glucose uptake in skeletal muscle.
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Abbreviations
AD Alzheimer’s disease
APP Amyloid precursor protein
BACE1 Beta-site APP-cleaving enzyme 1
EV Empty vector
HKII Hexokinase II
mBACE1 Mutant BACE1
MEM Minimal essential media
OCR Oxygen consumption rate
PI3K Phosphoinositide 3-kinase
PKB Protein kinase B
sAPP Soluble APP
Introduction
A fundamental characteristic of type 2 diabetes is the occur-
rence of insulin resistance in liver, adipose tissue and skeletal
muscle. However, the first detectable defect in individuals
predisposed to type 2 diabetes is altered responsiveness of
skeletal muscle to insulin [1, 2], the principal site for insulin-
stimulated glucose disposal [3]. Glucose transport is the rate-
limiting step for glucose metabolism in healthy and diabetic
D. Lee Hamilton, John A. Findlay and Gemma Montagut contributed
equally to this study.
D. L. Hamilton : J. A. Findlay :G. Montagut : P. J. Meakin :
D. Bestow : S. M. Jalicy :M. L. J. Ashford (*)
Division of Cardiovascular and Diabetes Medicine, Medical
Research Institute, Ninewells Hospital & Medical School,
University of Dundee, Dundee DD1 9SY, Scotland, UK
e-mail: m.l.j.ashford@dundee.ac.uk
Diabetologia (2014) 57:1684–1692
DOI 10.1007/s00125-014-3269-x
individuals [4, 5], with decreased insulin-stimulated glucose
uptake into skeletal muscle being a major contributory factor
to insulin resistance in patients with type 2 diabetes [6–8].
Insulin promotes glucose transport in skeletal muscle by stim-
ulating the translocation of the insulin-responsive glucose
transporter, GLUT4, from intracellular storage vesicles to
the plasma membrane [9]. In insulin-resistant humans, normal
total expression of GLUT4 is reported [10], but with
decreased cell surface levels [11, 12] due to reduced translo-
cation of GLUT4-containing vesicles [13]. Furthermore,
muscle-specific deletion of GLUT4 causes glucose intoler-
ance and diabetes inmice [14] with reduced insulin-stimulated
glucose uptake [15]. Conversely, muscle-specific overexpres-
sion of GLUT4 improves insulin action and decreases plasma
glucose levels in diabetic mice [16].
Some studies have linked type 2 diabetes to increased risk
of Alzheimer’s disease (AD), with AD patients being more
prone to impaired glucose metabolism, hyperinsulinaemia and
insulin resistance [17, 18]. A key feature of AD development
is enhanced proteolytic cleavage of the amyloid precursor
protein (APP) by the aspartyl protease, beta-site APP-
cleaving enzyme 1 (BACE1), which, with γ-secretase, raises
levels of β-amyloid peptides leading to amyloid aggregation
and plaque formation [19]. However, cleavage of APP by α-
secretases (e.g. a disintegrin and metalloprotease [ADAM]
family member) predominates under basal conditions.
BACE1 and α-secretase are sheddases, cleaving the extracel-
lular portions of APP and releasing their ectodomains (soluble
[s]APPβ and sAPPα, respectively) from the cell surface.
These soluble ectodomains may have physiological functions,
with sAPPα being neuroprotective and able to modulate cog-
nitive performance and neuronal plasticity [20].
Reduction or loss of BACE1 by genetic manipulation in
mice improves glucose disposal and insulin sensitivity on
regular and high-fat diets, and pharmacological inhibition of
BACE1 in mouse C2C12 myotubes increases insulin sensitiv-
ity [21]. In addition, BACE1 inhibition or overexpression in
C2C12 myotubes increases or decreases, respectively, insulin-
stimulated glucose uptake. This suggests that skeletal muscle
BACE1 activity is important in the regulation of insulin-
driven glucose disposal, but the mechanism by which this
occurs is unknown. Skeletal muscle glucose uptake has
insulin-dependent and insulin-independent components [22,
23]. Furthermore, in skeletal muscle from patients with type 2
diabetes, the insulin resistance associated with diminished
glucose uptake is probably due to post-receptor defect(s), with
impaired GLUT4 translocation to the plasma membrane [11,
23, 24]. As current therapies aimed at alleviating insulin
resistance and improving glucose uptake are insufficient and
often incompletely effective, there is an urgent need for
information on novel pathways that modulate GLUT4
translocation and glucose uptake which are amenable to
pharmacological intervention.
Consequently, we examined whether BACE1 activity and
APP processing in skeletal muscle modulates glucose uptake
primarily through altered insulin sensitivity or is capable of
engaging an insulin-independent pathway.
Methods
Cell culture L6-GLUT4myc rat myoblasts (kindly provided
by Amira Klip, Toronto, Canada) were maintained in
α-minimum essential media (MEM) with 10% FBS. C2C12
and L6-GLUT4myc myoblasts were differentiated to
myotubes as described previously [21]. C2C12 cells were
transfected with 12 μg DNA of empty vector (EV;
pcDNA3.1) or pcDNA3.1 containing full-length BACE1,
BACE1 active site mutant (mBACE1 [25]) or APP using
Lipofectamine 2000 (Invitrogen Life Technologies, Paisley,
UK). Cells were selectedwith 1mg/mlG418 (Sigma–Aldrich,
Gillingham, UK) and differentiated. A minimum of two inde-
pendently generated stable cell lines with concurrently pro-
duced EV controls was used. After 4 days of differentiation,
cells were treated with TAPI-1 (Invitrogen), Merck-3
(β-secretase inhibitor IV [M-3]), BACE1 inhibitor II,
batimastat, palmitate or D-erythro-sphingosine, N-acetyl-C2-
ceramide (all Calbiochem, Nottingham, UK), or appropriate
vehicle, overnight (∼20 h).
Cloning Full-length myc-his human BACE1 in pcDNA3.1
was obtained from GlaxoSmithKline (Harlow, UK).
mBACE1 (a gift from Professor Wolfe [Brigham and
Women’s Hospital, Boston, MA, USA]) was subcloned into
pcDNA3.1. Full-length human APP (Genbank AAH65529.1)
was amplified with primers APP Fwd: 5'-AAAGCTAGCATG
CTGCCCGGTTTG-3'; APP Rev: 5'-TTTAAGCTTCTAGT
TCTGCATCTGCTCAAA-3' and cloned into pcDNA3.1.
Immunoblotting and gene expression Protein isolation and
immunoblotting procedures were as described previously
[22]. For quantification of sAPP fragments, differentiated cells
were treated in 10 ml Optimem (Gibco Life Technologies,
Paisley, UK), and media were concentrated (30 kDa Amicon
Ultra 15 ml filter) by centrifugation (4,000g) and subjected to
SDS-PAGE with amounts presented relative to total protein.
Primary antibodies used were: anti-sAPPβ (Covance,
Alnwick, UK; 1:1,000), anti-sAPPα (IBL International, Ham-
burg, Germany; 1:50), anti-APP (Ab54, GlaxoSmithKline;
1:4,000), anti-phospho-PKB (protein kinase B; Ser473), anti-
PKB and anti-HKII (hexokinase II) (Cell Signaling, Hitchin,
UK; 1:1,000), anti-GLUT1 (Millipore, Nottingham, UK;
1:1,000) and anti-GLUT4 (Abcam, Cambridge, UK;
1:1,000). Glut1 (also known as Slc2a1), Glut4 (also known
as Slc2a4) and HkII (also known as Hk2) mRNA was deter-
mined by TaqMan RT-PCR (Applied Biosystems, Paisley,
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UK; Prism Model 7700) using commercial primers and
probe sets.
Cell surface GLUT4myc detection For details, see Wang et al
[26]. Briefly, L6-GLUT4myc myoblasts or myotubes were
serum-starved (4 h), treated withM-3 (250 nmol/l), stimulated
with insulin (20 or 100 nmol/l) or vehicle at 37°C for 30 min,
and fixed in 3% paraformaldehyde. Anti-c-myc (A14; Santa
Cruz, Heidelberg, Germany; 1:100) primary antibody was
applied (1 h), and peroxidase-conjugated rabbit anti-
mouse secondary antibody (1:1,000) in 3% goat serum
was added, followed by 1 ml o-phenylenediamine
dihydrochloride (OPD reagent; Sigma), and incubated
(in the dark) for 30 min. The reaction was stopped with
250 μl 3 mol/l HCl, and absorbance of the supernatant
fraction was measured.
Glucose uptake C2C12 myotubes, stably expressing BACE1,
APP or mBACE1, or EV controls were exposed to M-3
(250 nmol/l), BACE1 inhibitor II (0.7 μmol/l), palmitate
(750 μmol/l), ceramide (50 μmol/l) or batimastat (5 μmol/l).
Cells were serum-starved (2 h) and exposed to insulin
(100 nmol/l), sAPPα (0.3, 3 or 10 nmol/l), sAPPβ (0.3, 3 or
10 nmol/l) or vehicle control. For phosphoinositide 3-kinase
(PI3K)-dependence, myotubes were pretreated overnight with
M-3 or vehicle, then with wortmannin (100 nmol/l) for 1 h
before insulin. Myotubes were incubated (12 min) with
10 μmol/l 2-deoxy-D-[3H]glucose (2DG; 24.4 kBq/ml;
PerkinElmer, Cambridge, UK) at 20°C. Non-specific
uptake was determined using 10 μmol/l cytochalasin B
(Sigma–Aldrich). After lysis, cell-associated radioactivity
was measured (Beckman, High Wycombe, UK; LS 6000IC
scintillation counter), and protein was quantified using the
Bradford reagent.
Oxidation assays C2C12 myotubes pre-exposed to M-3
(250 nmol/l), BACE1 inhibitor II (0.7 μmol/l) or batimastat
(5 μmol/l) were incubated with 5 mmol/l glucose and
74 kBq/ml D-[U-14C]glucose (PerkinElmer) for 2 h at
37°C (glucose oxidation assay) or 5 mmol/l glucose and
750 μmol/l palmitate (conjugated to BSA)/[14C]palmitate
(74 kBq/ml) for 3 h (palmitate oxidation assay). Medium
was transferred to 15 ml centrifuge tubes, 14CO2 released
using 60% (v/v) perchloric acid was trapped by a Whatman
(GF/B) filter paper disc presoaked with 1 mol/l KOH, and
radioactivity was quantified by liquid-scintillation counting.
Immunostaining and imaging C2C12 myotubes were fixed in
4% paraformaldehyde, permeabilised in PBST (PBS+0.1%
Triton X-100), blocked in 10% donkey serum (Sigma–
Aldrich) and then incubated with primary antibodies:
anti-APP (Ab54, 1:100) or anti-BACE1 (Sigma–Aldrich,
1:250). Secondary antibodies were Cy3 (Jackson
ImmunoResearch, Newmarket, UK; 1:250) and Alexa Fluor
488 (Invitrogen, 1:250). Images were acquired with a confocal
laser-scanning microscope (Leica, Milton Keynes, UK; TCS
SP5 II).
Cellular respiration Myoblasts were seeded in XF 24-well
culture microplates (Seahorse Bioscience, Copenhagen,
Denmark), differentiated for 4 days and changed to Opti-
MEM-reduced serum medium incubated at 37°C (24 h). Cells
were washed in Krebs–Henseleit buffer (in mmol/l: 111 NaCl,
4.7 KCl, 2 MgSO4.7H2O and 1.2 Na2HPO4) containing
5 mmol/l glucose and 0.5 mmol/l L-carnitine, and baseline
recordings were taken to ensure a steady respiratory rate
before injection of palmitate (750 μmol/l).
Statistical analysis Comparisons between groups were per-
formed using an unpaired two-tailed Student’s t test, one-
sample Student’s t test or ANOVA with repeated measures
and Tukey’s multiple comparison test, as appropriate, using
GraphPad (Prism 5) software (GraphPad Software, La Jolla,
CA, USA). p values≤0.05 were considered significant.
Results
Glucose uptake and GLUT4 translocation in myotubes are
modulated by BACE1 activity in an insulin-independent
manner We detected BACE1 and APP protein in wild-type
C2C12 myoblasts and myotubes (Fig. 1a, b) and demonstrated
that BACE1 was proteolytically active by the presence of
sAPPβ in the incubation medium (Fig. 1c, d). Inhibition of
BACE1 activity by application of M-3 [27] to myotubes
before challenge with 100 nmol/l insulin increased insulin-
stimulated glucose uptake compared with insulin alone
(Fig. 1e). However, M-3, in the absence of insulin also in-
creased glucose uptake (Fig. 1e, f ). To confirm that this effect
was mediated by BACE1 inhibition, we treated wild-type
myotubes with a structurally dissimilar BACE1 inhibitor
(BACE1 inhibitor II), which increased glucose uptake
(Fig. 1f). Overexpression of mBACE1, which is devoid of
protease activity [25], also increased glucose uptake (Fig. 1g).
We also detected increased [14C]glucose incorporation in
M-3-treated C2C12 myotubes (Fig. 1h).
To examine the effect of BACE1 inhibition on plasma
membrane GLUT4 levels, we used rat differentiated L6
myotubes overexpressing GLUT4 with an exofacial myc-
epitope tag (GLUT4myc) [26]. Insulin (20 nmol/l) stimulation
of myotubes induced a gain in cell surface GLUT4myc
(Fig. 1i), as expected [27]. However, M-3 in the absence of
insulin also caused a gain in cell surface GLUT4myc, with
insulin (20 nmol/l) and M-3 producing an additive outcome
(Fig. 1i). Exposure of myotubes to a supramaximal insulin
concentration (100 nmol/l) in the absence and presence of
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M-3 resulted in a gain of cell surface GLUT4myc,
individually and additively indistinguishable from the
20 nmol/l insulin experiments (Fig. 1i). M-3 treatment
of GLUT4myc myoblasts also resulted in enhancement
of an insulin-dependent and insulin-independent gain in
cell surface GLUT4myc (Fig. 1j). These results strongly indi-
cate that BACE1 inhibition increases basal glucose uptake
through an insulin-independent pathway. M-3 had no effect
on Glut4, Glut1 or HkII mRNA expression (Fig. 2a–c) or
HKII protein levels, but modestly increased GLUT1 and
GLUT4 levels in C2C12 myotubes (Fig. 2d).
Palmitate and ceramide increase BACE1 and inhibit glucose
uptake Overexpression of BACE1 decreased insulin-
stimulated glucose uptake (Fig. 3a) and depressed basal glu-
cose uptake in C2C12 myotubes (Figs 3a, e and 5c). To address
whether manipulating BACE1 could affect glucose uptake in
the context of metabolic distress, we challenged C2C12
myotubes with the saturated fatty acid, palmitate. Palmitate
(750 μmol/l) inhibited insulin-stimulated glucose uptake in
the absence and presence of M-3 (Fig. 3b), although this was
associated with substantially increased BACE1 and APP pro-
tein levels (Fig. 3c). As the palmitate metabolite, ceramide,
mimics the effects of saturated fatty acid oversupply on insulin
sensitivity [28] and ceramide content is raised in skeletal
muscle of insulin-resistant rodents and humans [29, 30], we
decided to use this molecule to further examine M-3-sensitive
glucose uptake. Incubation of myotubes with ceramide
(50 μmol/l) decreased basal and M-3-stimulated glucose up-
take (Fig. 3d) and further suppressed glucose uptake inhibited
by BACE1 overexpression (Fig. 3e). However, ceramide also
increased myotube APP and BACE1 levels with decreased
sAPPα and increased sAPPβ levels (Fig. 3f, g). These
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Fig. 1 BACE1 inhibition increases glucose uptake and GLUT4 translo-
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uptake in control andM-3-treated myotubes (n=11); white bars, vehicle;
black bars, insulin. (f) 2DG uptake in myotubes treated with vehicle
(Veh), M-3 or BACE1 inhibitor (Inh) II (n=6–11). (g) 2DG uptake in
myotubes transfected with EVor mBACE1 (n=4). (h) Total [14C]glucose
incorporation in myotubes after vehicle and M-3 (n=4). (i, j) Gain in cell
surface GLUT4myc±insulin (Ins; 20 and 100 nmol/l)±M-3 in myotubes
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findings indicate that ceramide also inhibits the BACE1-
dependent, insulin-independent pathway of glucose uptake.
BACE1 activity alters substrate oxidation of C2C12 myotubes
The increased glucose uptake in skeletal muscle cells by
BACE1 inhibition was accompanied by increased glucose
oxidation (Fig. 4a, b), whereas BACE1 inhibition reduced
fatty acid (palmitate) oxidation (Fig. 4c). Real-time analysis
of the oxygen consumption rate (OCR) by C2C12 myotubes
confirmed that M-3 raised basal glucose oxidation, with no
change in glycolysis (Fig. 4d, e). Interestingly, M-3 had no
effect on myotube oxygen consumption in the presence of
glucose and palmitate (Fig. 4f ), indicating that decreased
BACE1 activity drives substrate switching to oxidise a greater
proportion of glucose over fatty acids to maintain ATP pro-
duction. Overexpression of BACE1 reduced glucose oxida-
tion (Fig. 4g), but did not affect palmitate oxidation (Fig. 4h).
These effects of increased BACE1 were confirmed by real-
time OCR analysis demonstrating reduced glucose oxidation
with unaltered myotube OCR in response to palmitate
(Fig. 4i, j) giving an overall reduced myotube oxygen con-
sumption for combined substrate (Fig. 4k).
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APP cleavage may mediate changes in glucose uptake by
BACE1 activity Exposure of myotubes to the α-secretase
inhibitors, TAPI-1 (20 μmol/l) and batimastat (5 μmol/l
[31]), depressed glucose uptake (Fig. 5a, b). Batimastat also
reduced insulin-stimulated glucose uptake (Fig. 5b) and po-
tentiated the depression of insulin-dependent and independent
glucose uptake by overexpression of BACE1 (Fig. 5c).
Batimastat treatment of C2C12 myotubes did not alter glucose
(Fig. 5d) or palmitate (Fig. 5e) oxidation or OCR in glucose
alone or glucose and palmitate (Fig. 5f, g). However,
batimastat-treated myotubes showed reduced ability to switch
substrate from glucose to palmitate in response to increased
substrate delivery (Fig. 5h), indicating diminished metabolic
flexibility. These data suggest that myotube α-secretase sub-
strate cleavage resulted in the maintenance or enhancement of
basal (insulin-independent) glucose uptake but did not affect
fuel oxidation. Indeed, APP is actively cleaved in C2C12
myotubes to shed sAPPα into the medium, an effect inhibited
by batimastat (Fig. 5i). A similar reduction was seen with
TAPI-1 (data not shown). Overexpression of APP in C2C12
myotubes increased basal and insulin-stimulated (Fig. 5j, k)
glucose uptake, but had little or no effect on glucose or
palmitate oxidation (Fig. 5l, m).
M-3-dependent glucose uptake is PI3K-dependent andmimicked
by sAPPα Insulin-stimulated GLUT4 translocation and glu-
cose uptake in skeletal muscle require activity of the PI3K–
PKB pathway [32]. Wortmannin (100 nmol/l) blocked the
increase in glucose uptake elicited by insulin (100 nmol/l),
as expected, and prevented M-3 from increasing glucose
uptake in C2C12 myotubes (Fig. 6a, b). Consistent with the
involvement of PI3K signalling in APP/BACE1-modulated
basal glucose uptake, the gain in cell surface GLUT4myc
caused by M-3, in the absence and presence of insulin, was
inhibited by wortmannin (Fig. 6c). To further explore the role
of α- and β-secretase APP cleavage, we examined the effects
of the respective cleavage products, sAPPα and sAPPβ on
activity in the PI3K–PKB pathway and glucose uptake. Incu-
bation of C2C12 myotubes with sAPPα increased phosphory-
lated PKB (Fig. 6d); this outcome was not replicated by
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sAPPβ (Fig. 6e). Furthermore, sAPPα increased glucose up-
take (Fig. 6f ), whereas sAPPβ had no effect (data not shown).
The sAPPα-mediated glucose uptake was additive to that of
insulin (Fig. 6g), as demonstrated for M-3 and APP overex-
pression. Taken together, these data suggest that modification
of skeletal muscle APP cleavage by α- and β-secretases
results in altered sAPPα abundance, which affects PI3K–
PKB signalling to alter GLUT4 translocation and glucose
uptake.
Discussion
Inhibition of BACE1 in rodent myotubes increases glucose
uptake and GLUT4 translocation independently of, but addi-
tive to, insulin-stimulated glucose uptake. Accordingly, re-
duced BACE1 activity increases insulin-stimulated glucose
uptake in agreement with our previous study [21]. Impairment
of insulin-stimulated glucose uptake by skeletal muscle is
recognised as an early defect in the pathogenesis of type 2
diabetes, although the ability of alternative stimuli such as
exercise/contraction to increase glucose uptake is unaffected
[33]. However, non-insulin-dependent (basal) glucose uptake
is also impaired in patients with type 2 diabetes. In the fasted
state, when plasma insulin levels are low and skeletal muscle
glucose uptake is insulin-independent, muscle glucose uptake
is decreased in insulin-resistant individuals [34, 35]. Conse-
quently, a novel pharmacological approach to increase
glucose disposal by targeting basal skeletal muscle glucose
uptake may have therapeutic utility.
Skeletal muscle glucose uptake occurs predominantly via
the insulin-sensitive transporter, GLUT4, although GLUT1
and GLUT12 are also expressed with GLUT1 and thought
to contribute to basal glucose uptake [36]. BACE1 inhibition
did not alter glucose transporter mRNA or HkII mRNA or
protein levels, although a small increase in GLUT1 and
GLUT4 protein levels was observed. Nevertheless, the major
effect of BACE1 inhibition was increased cell surface
GLUT4myc in the absence of insulin. The increased basal
and insulin-stimulated glucose uptake and GLUT4 translocation
elicited by BACE1 inhibition was prevented by wortmannin,
indicating a PI3K-regulated mechanism. Consequently, it is
likely that the increase in basal glucose uptake observed
following BACE1 inhibition is predominantly due to
enhanced translocation of GLUT4, through activation of the
canonical class 1A PI3K pathway [32].
Although we have not completely delineated the mecha-
nism by which BACE1 modulates glucose uptake, our results
indicate a key role for APP-cleavage products. APP mem-
brane processing occurs predominantly by α-secretases (the
‘non-amyloidogenic’ pathway), most likely ADAM10 [37].
This ectodomain-shedding process liberates a soluble truncat-
ed form of APP, sAPPα. In contrast, BACE1 (the
‘amyloidogenic’ pathway) cleaves APP at a different site
and releases a shorter soluble APP isoform, sAPPβ.
Thus α- and β-secretases compete for APP cleavage,
with the α-secretase pathway prevailing. Nevertheless, events
such as chronic stress raise BACE1 activity and increase
sAPPβ levels with a compensatory decline in sAPPα. Our
results strongly indicate a role for the α-secretase pathway in
modulating glucose uptake because: (1) α-secretase inhibition
reduces glucose uptake in conjunction with diminished sAPPα
in the medium; (2) APP overexpression (thus increased
sAPPα) enhances basal and insulin-dependent glucose uptake;
and (3) direct application of sAPPα increases basal and insulin-
dependent glucose uptake and PI3K signalling, whereas
sAPPβ does not affect either process.
Therefore we suggest that constitutive α-secretase activity
maintains basal glucose uptake in muscle cells, whereas in-
creased BACE1 activity inhibits this process by diverting APP
down the amyloidogenic pathway. This reduces sAPPα in the
medium and diminishes PI3K-driven GLUT4 translocation.
Indeed, sAPPα exhibits neuroprotective properties and in-
creases PI3K–PKB signalling and glucose uptake in neurons,
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effects not replicated by sAPPβ [38, 39]. These actions have
been attributed to the C-terminal part of sAPPα, which differs
from sAPPβ by the presence of an additional 16 amino acids.
Thus it is likely that this region is also responsible for the
increased glucose uptake and PI3K signalling in skeletal
muscle. The receptor by which sAPPα may mediate these
effects is at present unclear. However, sAPPα has structural
similarities to cysteine-rich growth factors [40] and its
neuroprotective function has been linked with activation
of IGF-1 receptor/insulin receptor PI3K–PKB signalling
in neurons [38].
The increased fat supply associated with obesity is a pri-
mary drive for the induction of skeletal muscle insulin resis-
tance. Fatty acids are an important fuel source for muscle, and
excess long-chain fatty acids, particularly saturated ones, in
skeletal muscle raise levels of the lipid intermediates, diacyl-
glycerol and ceramide, which are strongly implicated in the
pathogenesis of insulin resistance [41, 42]. The skeletal mus-
cle accumulation of diacylglycerol and ceramide is associated
with impaired insulin signalling predominantly via the PI3K–
PKB pathway [42, 43]. Exposure of C2C12 myotubes to
palmitate or ceramide depressed insulin-dependent and
-independent glucose uptake in the presence of BACE1
inhibitor. Thus the molecular mechanism underlying
BACE1 action, which requires PI3K activity, is also sensi-
tive to ceramide. Indeed, skeletal muscle BACE1 activity is
increased by high-fat diet [21], and the finding that cer-
amide, concomitant with high BACE1 activity, strongly
suppresses basal and insulin-dependent glucose uptake fits
with the idea that lowering of sAPPα reduces non-insulin-
dependent glucose uptake in muscle. Thus the balance
between α- and β-secretase activities may be an important
checkpoint in the control of skeletal muscle metabolism.
Accordingly, pharmacological reduction of BACE1, or in-
creased α-secretase activity, may represent a novel and
reasonable therapeutic target to improve glucose uptake in
tissues exposed to excess lipid.
BACE1 inhibition is also associated with increased glucose
oxidation in C2C12 myotubes, with an increased proportion
(over palmitate) of glucose oxidised for the same amount of
oxygen consumed. Such an action in vivo would raise post-
prandial glucose uptake and oxidation and increase overall
glucose disposal. Conversely, overexpression of BACE1
inhibited glucose oxidation and oxygen consumption with
no reduction in palmitate oxidation. Furthermore, inhibition
of α-secretase with batimastat reduced the increase in OCR
elicited by palmitate in the presence of glucose, indicating
diminished metabolic flexibility. Impairment of resting and
insulin-stimulated mitochondrial oxidative phosphorylation
has been reported in skeletal muscle of patients with type 2
diabetes [44, 45], and reduced glucose oxidation, with un-
changed lipid oxidation, has been found to be associated with
loss of metabolic flexibility in obese individuals [46]. At
present, the molecular mechanism whereby BACE1 reduces
glucose oxidation is unknown, with sAPPβ an unlikely me-
diator from our results. A plausible candidate is one or more of
the β-amyloid peptides resulting from the sequential cleavage
of APP by BACE1 and γ-secretase, as these aggravate the
diabetic phenotype of rodents [47, 48].
Taken together, our results indicate that preventing skeletal
muscle BACE1 activity from increasing excessively in times
of chronic nutrient stress may have important implications,
and indeed offer new therapeutic avenues, for the maintenance
of glucose uptake and oxidation and the preservation of
metabolic flexibility.
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